viewProactive Group

4D Pharma receives early boost from IBS trial

Early data from the phase I clinical trial appears to be encouraging.

4D is working on a drug to treat IBS.

4D Pharma (LON:DDDD) said an early stage clinical study of its drug candidate for irritable bowel syndrome (IBS) seems to be well tolerated by patients receiving it.

Interim data from the phase I trial of Blautix, conducted in both healthy volunteers and people with IBS, also “appears to support the pharmacological hypothesis” of the putative treatment, 4D said.

Chief scientific officer Alex Stevenson added: “We look forward to reporting further results from the trial shortly, when dosing in IBS patients is completed. 

“We believe our approach of identifying and developing novel live biotherapeutic products from healthy human samples gives us an advantage in terms of safety, and also allows us to rapidly develop drug candidates for diseases where current treatments may be associated with severe side effects."

Phase I studies are designed to test elements such as safety, dosing and how well tolerated the drug by the human body rather than efficacy.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Candelaria Mining executives eyeing to get Pinos Project Mine back into...

Candelaria Mining (CVE: CAND- OTC: CDELF) CEO Mike Struthers and Non-Executive Chairman Dr. Neil O’Brien joined Steve Darling from Proactive to provide an update on their arrival to the company which has just happened. Struthers giving an overview of where the company is at and what the plan for...

22 hours, 16 minutes ago

2 min read